Shionogi out-licenses COT-143 to AMR Centre

Japanese drugmaker Shionogi (TYO: 4507) has entered into an out-licensing agreement on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa, with the UK’s AMR Centre, based in Alderley Park, Cheshire.

Pseudomonas aeruginosa has remarkable ability to acquire resistance to antibiotics. As a consequence, the anti-pseudomonal agents that can be used against Pseudomonas aeruginosa infections and its infection-control measures are relatively limited1.

COT-143 is a humanized monoclonal antibody targeting the PcrV protein, which is involved in pathogenicity of Pseudomonas aeruginosa. Many non-clinical trials have demonstrated that COT-143 is effective in treatment and prevention of infection caused by Pseudomonas aeruginosa including multidrug-resistant one.